Simple daily activity could reduce risk of lower back pain, study finds
Researchers in Norway investigated how chronic low back pain, a "prevalent and costly condition," could be reduced by regular physical activity, including accessible walking.
The study, published in the journal JAMA Network Open, measured daily walking volume and walking intensity among more than 11,000 participants over the age of 20.
The participants then reported any incidences of lower back pain lasting three months or longer in the past year.
Walking for more than 100 minutes per day resulted in a 23% lower risk of pain compared to walking less than 78 minutes per day, according to the results.
For more Health articles, visit www.foxnews.com/health
Walking intensity was also associated with chronic lower back pain risk, but to a "lesser degree" than walking volume, researchers noted.
"In this cohort study, daily walking volume and walking intensity were inversely associated with the risk of chronic [lower back pain]," the study concluded.
"The findings suggest that walking volume may have a more pronounced benefit than walking intensity."
"These findings suggest that policies and public health strategies promoting walking could help to reduce the occurrence of chronic [lower back pain]."
Dr. Arthur L. Jenkins III, board-certified neurosurgeon and founder of Jenkins NeuroSpine in New York City, confirmed in an interview with Fox News Digital that long walks "are good," as long as other orthopedic issues don't make it difficult to walk.
"I always encourage my patients to walk, and to engage their core (squeeze their abs and back) while walking to exercise more than just their legs, and straighten their backs," he advised.
Statistics show that more than one-quarter of Americans report experiencing chronic lower back or sciatic pain.
Fox News Digital reached out to the study authors for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
Fox News
2 hours ago
- Fox News
Francis Ford Coppola's treatment sheds light on heart condition affecting millions
Francis Ford Coppola, director of "The Godfather," was hospitalized in Italy last week for a non-emergency cardiac procedure. The filmmaker, 86, sought to update a "30-year-old AFib procedure," according to a post on his Instagram page. AFib, or atrial fibrillation (AFib), is an "irregular and often rapid heart rhythm" that can raise the risk of blood clots, heart failure, stroke and other heart-related complications, according to the American Heart Association. After Italian media sources reported the director's hospital visit, a representative for Coppola called it a "scheduled update procedure" and said he was "resting nicely." "All is well," according to his representatives. "Da Dada (what my kids call me) is fine," the director said on his social media, speaking for what appears to be the first time about his condition. He continued: "Taking an opportunity while in Rome to do the update of my 30-year-old AFib procedure with its inventor, a great Italian doctor — Dr. Andrea Natale! I am well!" Dr. Bradley Serwer, an interventional cardiologist and chief medical officer at VitalSolution, an Ingenovis Health company, spoke with Fox News Digital about the condition. "AFib is typically not immediately life-threatening, but it can lead to complications or issues in the future," said the cardiologist, who has not treated Coppola. With AFib, the normal electrical activity in the heart changes to chaotic electrical signals, according to the Maryland-based cardiologist. This causes the heart to beat quickly and get out of rhythm. Instead of contracting normally, the upper chambers of the heart — called atria — start to quiver, causing blood clots to form. "When these clots break free, they can travel to the brain, causing a stroke," Serwer cautioned. For many people, AFib may have no symptoms, but for some, it can cause a fast or pounding heartbeat, shortness of breath or lightheadedness. "AFib can be challenging due to its diverse manifestations," Serwer noted. There are several procedural approaches to treat atrial fibrillation, according to the cardiologist. The most common procedure is called an ablation, which is when a specialized cardiologist uses catheters to follow the heart's electrical activity. The doctor then burns the sites where the AFib begins. "This procedure has a high rate of success and complications are low, making it a highly valued option," Serwer noted. If a patient is undergoing open-heart surgery for coronary artery disease or valvular heart disease, a surgeon can perform a "maze procedure," which creates a "maze-like pattern of scar tissue" in the upper chambers of the heart to block irregular electrical signals, according to Mayo Clinic. There are also procedures to reduce the risk of stroke in patients who have AFib, but who may not be able to take blood thinners. By placing a small device where blood clots form, the rate of stroke drops significantly, Serwer said. In some cases of atrial fibrillation, the condition can come and go, but other patients may experience persistent AFib, the cardiologist said. For more Health articles, visit While it's not usually life-threatening, AFib is still considered a serious medical condition that requires proper treatment. Serwer advised, "If you experience sudden-onset dizziness or palpitations that persist, it is imperative to seek immediate evaluation from a medical professional."
Yahoo
4 hours ago
- Yahoo
New Dad, 29, Was Told He Had Tonsillitis. He Died the Next Day
"Watching Jacob grow up without his daddy by his side is devastating and we miss Michael every single day," Charlotte Reynolds said NEED TO KNOW A new father died a day after he was allegedly misdiagnosed with tonsillitis Michael Reynolds, 29, actually had the potentially fatal condition epiglottitis, which causes a swelling of the flap at the top of the windpipe He had a seizure at home and later died of cardiac arrest, caused by a lack of oxygen, per his family's law firm, Irwin Mitchell A new father died a day after doctors allegedly misdiagnosed him with tonsillitis. Michael Reynolds, a 29-year-old truck driver, first sought medical care on November 29, 2023, when he complained of a lingering cough and sore throat. He was prescribed a steroid nasal spray and referred for a chest X-ray, according to a statement from the family's law firm, Irwin Mitchell. Michael's condition deteriorated the following day, and he returned to his doctor's office, where he saw a different physician. At the time, Michael said he felt like his throat was closing up, and he was spitting saliva into a bowl because he couldn't swallow. He was allegedly diagnosed with tonsillitis — inflammation of the tonsils — and prescribed oral antibiotics. The family's law firm alleges it was 'not made clear' to Michael that he should go to the emergency room. After leaving the doctor's office, Michael and his wife, Charlotte, picked up his antibiotics from the pharmacy and returned to their home in Boston, Lincolnshire, in the U.K. The next morning, Michael had a seizure; Charlotte called an ambulance which took him to the hospital, where he died on Dec. 1, 2023. According to Irwin Mitchell, the coroner found that Michael had epiglottitis, which is a swelling of the flap that covers the windpipe. As the Cleveland Clinic explains, it's an uncommon condition, most likely caused by a bacterial infection, and shouldn't be treated at home. According to the Clinic, "It's essential to get to the emergency room (ER) immediately if you or a loved one is experiencing symptoms of epiglottitis. Epiglottitis is a medical emergency." The epiglottitis and upper airway obstruction led to Michael's hypoxic cardiac arrest — aka, cardiac arrest caused by a lack of oxygen. Per Irwin Mitchell, an inquest into his death found there was a 'missed opportunity' to give Michael 'robust advice' to go to the emergency room, per the coroner, who explained that staff there would likely have been more familiar with the condition. 'This is a truly tragic case where a young dad has lost his life. Charlotte and the rest of Michael's family are understandably struggling to come to terms with losing him so suddenly and unexpectedly, and under such circumstances,' Rosie Charlton, the family's attorney, said. 'They've also had a number of concerns about the events that unfolded in the lead up to Michael's death. Worryingly, the inquest has validated those concerns.' 'Watching Jacob grow up without his daddy by his side is devastating and we miss Michael every single day,' Charlotte, whose son is now 3, said in the Irwin Mitchell statement. "Michael meant everything to us and losing him has left a huge hole in our lives that will never go away. We'd do anything to bring him back.' PEOPLE has reached out to Charlotte Reynolds for further comment. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Her statement to Irwin Mitchell continued: 'All I can hope for now is that by sharing our story, it can lead to improvements in care for others and more awareness around the signs of epiglottitis and the need for emergency treatment, as it's something I'd never even heard of before.' 'I wouldn't want anyone going through what we have.' Read the original article on People Solve the daily Crossword
